Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
605 days ago
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
860 days ago
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
887 days ago
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
959 days ago
U.S. Dollar Falls Against Majors
The U.S. dollar weakened against its major counterparts in the New York session on Monday, as investors focused on upcoming earnings announcements and some crucial U.S. economic data.
RTTNews
|
37 minutes ago
Swiss Market Ends On Firm Note
After a flat start and a subsequent sluggish spell the Switzerland market moved higher on Monday with stocks gradually gaining in strength as the day progressed.
RTTNews
|
2h 4min ago
European Stocks Close Broadly Higher Ahead Of Earnings Announcements
European stocks closed higher on Monday, and the U.K. market recorded its longest winning streak in over five years, moving up for the eleventh consecutive session, as investors focused on upcoming earnings announcements and some crucial European and U.S. economic data.
Hopes of a de-escalation in U.S.-China trade friction too contribute to the positive mood in the market.
RTTNews
|
2h 16min ago
Domino's Pizza Q1 Earnings Beat, Revenues Miss, U.S. Same Store Sales Down; Stock Drops
Domino's Pizza Inc. announced Monday higher earnings in its first quarter, above market estimates, amid revenue growth. Meanwhile, the largest pizza company in the world recorded weak income from operations and U.S. same store sales, and its top line missed the Street view. In pre-market activity on the Nasdaq, Domino's Pizza shares were losing around 2.6 percent.
RTTNews
|
6h 50min ago
